NEW YORK, Jan. 12, 2011 /PRNewswire/ -- InstaCare Corp. (OTC Bulletin Board: ISCR) a leading provider of prescription and non-prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that the company's Board of Directors has received the initial Guidance Report from Mr. William N. Walling, Jr., CFA. This report covers the 2011 guidance for the company's new Genstrip diagnostic product being sold exclusively through the company's Pharma Tech Solutions, Inc. subsidiary. The entire report is currently available for viewing on the company's website www.instacare.net.
Mr. Walling, an expert financial analyst specializing in the domestic healthcare paradigm, was contracted to review the company's performance, its progress with project development, product pipeline advancement, new product introduction (Genstrip) and financial results versus the stated plan. Mr. Walling's report includes an expectation of continued strength and market growth of current product offerings, and substantial industry traction with the company's new Genstrip diagnostic product with substantial revenue and margin contribution potential.
Keith Berman, Secretary and CFO of InstaCare Corp., commented: "Mr. Walling's report reinforces our internal confidence in the company's business model and strategic direction. This report concerning our new Genstrip diagnostic product should assure the investment community and company's shareholders that management and the BOD have faithfully executed the tasks documented in our plan enabling the attainment of all identified benchmarks. It should also confirm the validity of the company's business model and the viability of our continued success going forwa